IHEEZO
Peakchloroprocaine hydrochloride ophthalmic gel
NDAOPHTHALMICGEL
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
IHEEZO (chloroprocaine hydrochloride ophthalmic gel) is 12. First approved in 2022.
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IHEEZO is a topical ophthalmic gel containing chloroprocaine hydrochloride, a local anesthetic that blocks nerve impulse generation and conduction in the eye. It is indicated for corneal anesthesia during ophthalmic procedures. The drug works by increasing the electrical excitation threshold in nerve fibers, progressively blocking pain sensation followed by temperature, touch, proprioception, and muscle tone.
Peak13.0 years to LOE
Product is in peak commercial phase with strong patent protection, suggesting stable market positioning and maintained team investment through at least 2039.
Mechanism of Action
12.1 Mechanism of Action 12.1 Mechanism of Action Chloroprocaine, like other local anesthetics, blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.